• Exemestane: Steroidal Aromatase Inhibitor Guide

  2026-09-11

  Exemestane is a selective, irreversible steroidal aromatase inhibitor used to study estrogen biosynthesis inhibition. The A1296 product is characterized by nanomolar activity against human placental aromatase and is supplied for breast cancer research and hormone-related studies.

• Malate as a Translational Probe of Tumor Metabolism

  2026-09-10

  Malate is more than a tricarboxylic acid cycle intermediate: it is a controllable entry point for testing mitochondrial flux, redox balance, and immune-metabolic communication. This thought-leadership guide connects malate perturbation to the PDHA1 succinylation mechanism reported in cholangiocarcinoma while separating established evidence from forward-looking workflow recommendations.

• Sodium chloride: Buffer and QC Workflow

  2026-09-10

  Sodium chloride is an inorganic salt used to set ionic strength and support osmotic balance in buffer preparation, cell culture media, and related biochemical workflows. It should be dissolved in water and used promptly; it is not a suitable solvent for DMSO- or ethanol-based preparations and should not be treated as a pH buffer or a substitute for sterility-qualified reagents.

• Isoliensinine, Lipid Droplets, and MAFLD Fibrosis

  2026-09-09

  The reference study identifies a TRPV1–AMPK/ACC mechanism through which isoliensinine from Plumula Nelumbinis restores lipid droplets in hepatic stellate cells and attenuates MAFLD-associated fibrosis. Its combination of complementary animal models, LX-2 cell experiments, and molecular assays provides a useful framework for studying lipid droplet metabolism as a regulator of fibrogenesis.

• LLY-507: From Target Engagement to Cell Phenotype

  2026-09-09

  LLY-507 is a selective SMYD2 inhibitor for connecting methyltransferase target engagement with cancer cell phenotypes. This guide develops an evidence-based assay framework that separates direct SMYD2 inhibition from downstream proliferation, apoptosis, and fibrosis-related effects.

• Chronic Cabozantinib Rewires RCC Phosphosignaling

  2026-09-08

  This 2026 study uses quantitative phosphoproteomics to distinguish acute cytostatic signaling from chronic adaptation during Cabozantinib exposure in renal cell carcinoma. Its main contribution is the integration of phosphorylation-network remodeling with migration and invasion assays, showing sustained MET activation-loop suppression alongside selective adhesion- and stress-associated changes after long-term treatment.

• ECL Chemiluminescent Substrate Kit for Ferroptosis

  2026-09-07

  The ECL Chemiluminescent Substrate Detection Kit can convert ferroptosis pathway questions into sensitive, interpretable protein measurements. This guide uses TRIB3–SLC7A11–GPX4 research to explain assay design, signal interpretation, controls, and the limits of ECL-based evidence.

• α7nAChR, Pyroptosis, and HIV-1 BBB Injury

  2026-09-07

  The reference study identifies α7nAChR-driven pyroptosis in brain microvascular endothelial cells as a previously unrecognized mechanism of HIV-1 gp120-induced blood–brain barrier disruption. Its mechanistic analysis connects α7nAChR to the ROS/NF-κB/NLRP3 axis and shows that memantine and metformin can suppress this injury pathway in experimental models.

• Tolazoline Workflows for α2-Adrenergic Signaling

  2026-09-05

  Tolazoline enables controlled interrogation of α2-adrenergic signaling in airway and pancreatic islet models, with concentration ranges that help separate receptor antagonism from ATP-sensitive potassium channel effects. This workflow-focused guide covers exposure design, functional readouts, troubleshooting, and the limits of translating continuous-delivery concepts into bench assays.

• CXCR4–EGFR Heteromers Rewire Cancer Signaling

  2026-09-05

  Comez and colleagues show that CXCR4 and EGFR assemble into ligand-sensitive oligomeric signaling complexes rather than acting only as independent receptors. By combining NanoBRET with nanobody-based proximity ligation assays, the study links receptor proximity to altered Gi, PLCγ, and β-arrestin-2 coupling and validates the complexes in native HeLa cells.

• Novel PDK4 Inhibitors for Metabolic Disease

  2026-09-04

  The 2019 Journal of Medicinal Chemistry study identified compound 8c as an allosteric pyruvate dehydrogenase kinase 4 inhibitor with nanomolar in vitro activity and activity in mouse models of glucose intolerance and allergic reactions. Its combination of structure-based optimization, pharmacokinetic characterization, in vivo testing, and docking provides a useful framework for evaluating PDK4 as a multidisease drug-discovery target.

• Nigericin Sodium Salt for Ion Transport Assays

  2026-09-04

  Nigericin sodium salt provides a practical way to perturb K+/H+ exchange, cytoplasmic pH, and membrane ion gradients in controlled in vitro systems. This guide connects ionophore workflows with time-resolved cancer drug-response measurements, platelet aggregation modulation, and exploratory lead (Pb2+) ion transport studies.

• Neuromedin S (rat): Protocol and QC Guide

  2026-09-03

  Neuromedin S (rat) provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling in rat-oriented research workflows. This guide covers preparation, storage, assay controls, and troubleshooting; it does not establish therapeutic, diagnostic, cross-species, or literature-validated dosing conditions.

• dKeap1–Lamin Dm0 and Nuclear Architecture

  2026-09-02

  Carlson and colleagues identify a functional interaction between Drosophila Keap1 and the B-type lamin Dm0, extending Keap1 biology beyond xenobiotic-responsive transcription. Their results connect dKeap1 misregulation with lamin redistribution, heterochromatin-marker spreading, nuclear-lamina defects, and developmental genetic interaction.

• CS-NAC Nanoparticles Suppress Ferroptosis in OA

  2026-09-02

  A 2025 Small Science study developed chondroitin sulfate-modified PLGA nanoparticles to deliver N-acetylcysteine directly to chondrocytes in osteoarthritis. The formulation sustained local antioxidant activity, maintained glutathione and GPX4 function, reduced ferroptosis, and protected cartilage more effectively than free NAC or nontargeted nanoparticles in a murine model.

8590 records 2/573 page Previous Next 12345 下5页 Last page